Other DDR inhibitors used along with definitive chemotherapy are underway, including DNA‐PK inhibitor M9831, the Phase I evaluation of which was completed in 2019 to determine the maximum tolerated dose of M9831 and its efficacy with or without doxorubucin in advanced cancer patients (NCT02644278). The gene discussed is PRKDC; the disease is cancer.